A novel coumarin ruthenium anticancer complex, its synthesis method and application
By synthesizing a novel coumarin-ruthenium anticancer complex YNU-5a–YNU-5d, the problem of poor inhibitory effect on drug-resistant human lung cancer cells in existing technologies has been solved, and effective inhibition of drug-resistant human lung cancer cell line A549/DDP has been achieved, which has potential medicinal value.
Patent Information
- Application Number
- CN202410566163.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-09
- Publication Date
- 2026-11-17
AI Technical Summary
Existing ruthenium coumarin compounds have poor inhibitory effects on human lung cancer drug-resistant cells A549/DDP, and ruthenium anticancer complexes of coumarin derivatives pyc1–pyc4 have not been reported.
A novel coumarin-ruthenium anticancer complex, YNU-5a–YNU-5d, was synthesized by coordinating cis-Ru(DMSO)4Cl2 with four coumarin derivatives pyc1–pyc4 under specific solvent and temperature conditions and then purifying the product by Al2O3 column chromatography to obtain a reddish-brown product.
The novel coumarin-ruthenium complex exhibits superior antitumor activity against the drug-resistant human lung cancer cell line A549/DDP, overcoming cisplatin resistance and possessing potential medicinal value.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] This invention belongs to the field of drug development technology, specifically relating to a novel coumarin ruthenium anticancer complex, its synthesis method, and its application. Background Technology
[0002] Coumarins are a class of natural compounds with a benzo-α-pyran structure, widely studied for their small molecular weight, simple synthesis, and high bioavailability. Numerous studies have shown that coumarins and their derivatives possess anti-inflammatory, antioxidant, antiviral, and antitumor effects. In recent years, metal-based antitumor drugs have gained increasing favor among researchers, who have begun to incorporate coumarin groups into metal drugs to enhance their antitumor activity.
[0003] Coumarin ruthenium complexes exhibit extremely high anticancer effects against NCI-H460 cancer cells, with an inhibitory effect of 0.30 ± 0.02 µM (Liang, H.; et al. ACS Med. Chem. Lett. 2019, 10, 936-940). However, there is still a gap in the application of coumarin ruthenium compounds against drug-resistant human lung cancer A549 / DDP cells, and ruthenium anticancer complexes of coumarin derivatives pyc1–pyc4 have not yet been reported.
[0004] The information disclosed in this background section is intended only to enhance the understanding of the overall background of the invention and should not be construed as an admission or in any way implying that the information constitutes prior art known to those skilled in the art. Summary of the Invention
[0005] In view of the shortcomings of the prior art, the purpose of this invention is to provide an antitumor and antibacterial compound and its application.
[0006] The technical solution provided by this invention is as follows:
[0007] A novel coumarin ruthenium anticancer complex, wherein the novel coumarin ruthenium anticancer compound is complex 1 or complex 2;
[0008] The structural formula of the complex 1 is as follows:
[0009]
[0010] The structural formula of the complex 2 is as follows:
[0011]
[0012] Wherein, R1 is H or CH3; R2 is H or OCH3; and R3 is H.
[0013] Preferably, the synthesis method of complex 1 or complex 2 is as follows: 1.0 mmol of coumarin derivative pyc1–pyc4 and an equal amount of cis-Ru(DMSO)4Cl2 are added to a 15.0 cm thick-walled drug-resistant tube, followed by 3.0 mL of a mixed solution of methanol and dichloromethane (v / v, 1:10). After capping the drug-resistant bottle, the mixture is reacted at 50-90℃ (68℃ being the optimal temperature) for 3 days. After cooling to room temperature, the cap is opened, and the mixture is filtered to obtain the crude product. Then, using CH2Cl2 / MeOH (v / v, 1:100~1:40) as the eluent, the product is purified by Al2O3 column chromatography to obtain a reddish-brown product, which is complex 1 or complex 2.
[0014] Preferably, the coumarin derivative has the following structural formula:
[0015] or
[0016] Wherein, R1 is H or CH3; R2 is H or OCH3; and R3 is H.
[0017] The present invention also provides the application of the novel coumarin ruthenium anticancer complex in the preparation of antitumor drugs.
[0018] Preferably, the tumor is human lung cancer.
[0019] The present invention also provides an in vitro and in vivo antitumor drug, wherein the novel coumarin ruthenium anticancer complex is the active ingredient.
[0020] Compared with the prior art, the present invention has the following beneficial effects:
[0021] This invention synthesizes four novel coumarin-ruthenium complexes by coordinating cis-Ru(DMSO)4Cl2 as a metal salt with four coumarin derivatives. Anticancer activity and toxicity experiments on the drug-resistant human lung cancer cell line A549 / DDP and normal HEK293 cells revealed that the novel coumarin-ruthenium complexes of this invention have a good inhibitory effect on the drug-resistant human lung cancer cell line A549 / DDP. This indicates that the four novel coumarin-ruthenium anticancer compounds YNU-5a–YNU-5d of this invention exhibit superior antitumor activity, while overcoming cisplatin resistance, and possess potential pharmaceutical value, with promising applications in the preparation of various antitumor drugs. Attached Figure Description
[0022] Figure 1 is The proton NMR spectrum of coumarin-derived pyc1 obtained in Example 1 of this invention;
[0023] Figure 2 isThe proton NMR spectrum of coumarin-derived pyc2 obtained in Example 1 of this invention;
[0024] Figure 3 is The proton NMR spectrum of coumarin-derived pyc3 obtained in Example 1 of this invention;
[0025] Figure 4 is The proton NMR spectrum of coumarin-derived pyc4 obtained in Example 1 of this invention;
[0026] Figure 5 is The proton nuclear magnetic resonance spectrum of the complex YNU-5a obtained in Example 1 of this invention;
[0027] Figure 6 is The proton NMR spectrum of the complex YNU-5b obtained in Example 1 of this invention;
[0028] Figure 7 is The proton NMR spectrum of the complex YNU-5c obtained in Example 1 of this invention;
[0029] Figure 8 is X-ray single-crystal diffraction pattern of the complex YNU-5d obtained in Example 1 of this invention. Detailed Implementation
[0030] The specific embodiments of the present invention will be described in detail below with reference to the examples, but it should be understood that the scope of protection of the present invention is not limited to the specific embodiments.
[0031] Unless otherwise expressly stated, throughout the specification and claims, the term "comprising" or its variations such as "including" or "comprises" shall be understood to include the stated elements or components without excluding other elements or other components.
[0032] Example 1 :
[0033] In a 250 mL round-bottom flask, 0.05 mol of 2-pyridineacetonitrile (py) and 0.05 mol of salicylaldehyde (c1), 3-methylsalicylaldehyde (c2), 2-hydroxy-4-methoxybenzaldehyde (c3), or 2-hydroxy-1-naphthaldehyde (c4) were weighed out. Then, 30.0 mL of anhydrous ethanol and 1.0 mL of piperidine were added. The mixture was stirred at 37 °C for 12 h, then reacted at 65 °C for 12 h. The mixture was filtered to obtain iminocoumarin derivatives y1–y4. Finally, these derivatives were added to a 500 mL round-bottom flask, followed by 35.0 mL of HCl (15.0%) and 5.0 mL of H2O. The mixture was reacted at 95 °C for 12 h. The acidic solution was neutralized with concentrated ammonia water, and the mixture was filtered to obtain a pale yellow solid. The solid was then heated with 10.0 mL of HCl. The solid was dissolved and recrystallized in mL of methanol, repeated 3 times, and filtered to finally obtain a pure light yellow product pyc1–pyc4 with a yield of 77.2-85.9%.
[0034] In a 15.0 cm thick-walled drug-resistant tube, 1.0 mmol of coumarin derivatives pyc1–pyc4 and an equimolar amount of cis-Ru(DMSO)4Cl2 were added, followed by 3.0 mL of a methanol and dichloromethane mixture (v / v, 1:10). After capping the drug-resistant tube, the mixture was reacted at 68 °C for 3 days. The mixture was then cooled to room temperature, the cap was opened, and the mixture was filtered to obtain the crude product. The crude product, YNU-5a–YNU-5d, was then purified by Al2O3 column chromatography using CH2Cl2 / MeOH (v / v, 1:100–1:40) as the eluent. The yield was 85.4–92.6%.
[0035] The obtained product was identified as follows:
[0036] (1) The nuclear magnetic resonance hydrogen spectrum of the compound is shown in Figure 1-7.
[0037] Data for pyc1. Yield: 77.2%. 1H NMR (400 MHz, DMSO-d6): δ 8.89 (s,1H), 8.79 (d, J = 4.3 Hz, 1H), 8.33 (d, J = 8.1 Hz, 1H), 8.14 (td, J = 7.9,1.7 Hz, 1H), 7.93 (dd, J = 7.7, 1.5 Hz, 1H), 7.71 (m, 1H), 7.63 (ddd, J =7.5, 5.1, 0.9 Hz, 1H), 7.50 (d, J = 8.3 Hz, 1H), 7.43 (td, J = 7.6, 1.0 Hz,1H).
[0038] Data for pyc2. Yield: 79.5%. 1 H NMR (400 MHz, DMSO-d6): δ 8.83 (s,1H), 8.70 (ddd, J = 4.7, 1.8, 0.9 Hz, 1H), 8.27 (dt, J = 8.1, 0.9 Hz, 1H),7.91 (td, J = 7.8, 1.9 Hz, 1H), 7.74 (dd, J = 7.8, 0.9 Hz, 1H), 7.53 (d, J =7.4 Hz, 1H), 7.43 (ddd, J = 7.5, 4.7, 1.1 Hz, 1H), 7.29 (t, J = 7.6 Hz, 1H),2.41 (s, 3H).
[0039] Data for pyc3. Yield: 81.2%. 1 H NMR (400 MHz, DMSO-d6): δ 8.88 (s,1H), 8.77 (ddd, J = 5.1, 1.7, 0.8 Hz, 1H), 8.34 (d, J = 8.1 Hz, 1H), 8.16(td, J = 7.9, 1.7 Hz, 1H), 7.84 (d, J = 8.7 Hz, 1H), 7.62 (ddd, J = 7.5, 5.1,1.0 Hz, 1H), 7.11 (d, J = 2.4 Hz, 1H), 7.04 (dd, J = 8.7, 2.4 Hz, 1H), 3.90(s, 3H).
[0040] Data for pyc4. Yield: 85.9%.1 H NMR (400 MHz, DMSO-d6): δ 9.68 (s,1H), 8.90 (ddd, J = 5.2, 1.6, 0.7 Hz, 1H), 8.67 (d, J = 8.3 Hz, 1H), 8.52 (d,J = 8.1 Hz, 1H), 8.33 (dd, J = 7.5, 1.9 Hz, 1H), 8.31 (d, J = 8.7 Hz, 1H),8.10 (d, J = 7.9 Hz, 1H), 7.79 (d, J = 8.3 Hz, 1H), 7.82 – 7.75 (m, 1H), 7.69– 7.64 (m, 1H), 7.66 (d, J = 9.0 Hz, 1H).
[0041] Data for YNU-5a. Yield: 89.9%. 1 H NMR (400 MHz, DMSO-d6): δ 8.89 (s,1H), 8.77 (d, J = 4.2 Hz, 1H), 8.31 (d, J = 8.1 Hz, 1H), 8.06 (t, J = 7.8 Hz,1H), 7.94 (dd, J = 7.7, 1.4 Hz, 1H), 7.71 (t, J = 7.8 Hz, 1H), 7.56 (dd, J =7.0, 5.4 Hz, 1H), 7.50 (d, J = 8.3 Hz, 1H), 7.43 (t, J = 7.5 Hz, 1H), 2.54(s, 12H).
[0042] Data for YNU-5b. Yield: 85.4%. 1 H NMR (400 MHz, DMSO-d6): δ 8.87 (s,1H), 8.72 (dd, J = 4.7, 0.7 Hz, 1H), 8.29 (d, J = 8.0 Hz, 1H), 7.94 (td, J =7.8, 1.8 Hz, 1H), 7.78 (d, J = 7.2 Hz, 1H), 7.56 (d, J = 7.2 Hz, 1H), 7.46(ddd, J = 7.5, 4.8, 0.9 Hz, 1H), 7.32 (t, J = 7.6 Hz, 1H), 2.55 (s, 12H),2.43 (s, 3H).
[0043] Data for YNU-5c. Yield: 90.3%. 1 H NMR (400 MHz, DMSO-d6): δ 8.88 (s,1H), 8.77 (d, J = 7.4 Hz, 1H), 8.34 (d, J = 8.1 Hz, 1H), 8.13 (td, J = 8.0,1.5 Hz, 1H), 7.86 (d, J = 8.7 Hz, 1H), 7.60 (dd, J = 6.6, 5.3 Hz, 1H), 7.12 (d, J = 2.4 Hz, 1H), 7.04 (dd, J = 8.7, 2.4 Hz, 1H), 3.91 (s, 3H), 2.54 (s,16H).
[0044] Data for YNU-5d. Yield: 92.6%.
[0045] (2) Elemental analysis results are shown in Table 1.
[0046]
[0047] (3) The infrared spectral data of the compound are shown below.
[0048] Data for YNU-5a. Yield: 89.9%. IR (KBr): 3037, 3450, 3229, 3103,3089, 3049, 3007, 2920, 2831, 2582, 2361, 2010, 1725, 1696, 1680, 1608, 1592,1566, 1539, 1525, 1491, 1431, 1405, 1372, 1309, 1289, 1243, 1223, 1197, 1167,1135, 1101, 1084, 1022, 974, 931, 923, 881, 838, 795, 781, 765, 742, 719,677, 641, 618, 580, 552, 523, 457, 424 cm −1 .
[0049] Data for YNU-5b. Yield: 85.4%. IR (KBr): 3929, 3419, 3121, 3021,2962, 2924, 2823, 1978, 1933, 1724, 1639, 1591, 1480, 1462, 1441, 1378, 1313, 1293, 1275, 1240, 1211, 1191, 1088, 1068, 1020, 970, 932, 920, 891, 874, 801,782, 750, 734, 720, 705, 682, 647, 633, 569, 536, 515, 457, 445, 427 cm −1 .
[0050] Data for YNU-5c. Yield: 90.3%. IR (KBr): 3934, 3446, 3077, 3031,3014, 2924, 2827, 2591, 2007, 1706, 1691, 1648, 1616, 1588, 1558, 1525, 1501,1460, 1445, 1404, 1380, 1365, 1312, 1281, 1269, 1230, 1174, 1132, 1100, 1022,995, 973, 951, 935, 919, 866, 847, 825, 792, 760, 738, 719, 679, 639, 618,584, 552, 526, 483, 425 cm −1 .
[0051] Data for YNU-5d. Yield: 92.6%. IR (KBr): 3429, 3225, 3144, 3129,3105, 3066, 3023, 2998, 2925, 2879, 2837, 2758, 1966, 1916, 1717, 1695, 1638,1596, 1573, 1532, 1483, 1466, 1457, 1435, 1415, 1400, 1374, 1353, 1310, 1281,1248, 1203, 1176, 1144, 1106, 1096, 1020, 1004, 967, 940, 931, 916, 898, 889,794, 782, 760, 749, 738, 713, 690, 679, 633, 617, 594, 583, 556, 521, 479,447, 423cm −1 .
[0052] (4) X-ray single-crystal diffraction pattern of compound YNU-5d, as shown Figure 8 Show.
[0053] Therefore, the structural formula of the target product can be determined as follows:
[0054]
[0055] Example 2 :
[0056] In a 15.0 cm thick-walled drug-resistant tube, 1.0 mmol of coumarin derivatives pyc1–pyc4 and an equimolar amount of cis-Ru(DMSO)4Cl2 were added, followed by 3.0 mL of a methanol and dichloromethane mixture (v / v, 1:10). After capping the drug-resistant tube, the mixture was reacted at 55 °C for 3 days. The mixture was then cooled to room temperature, the cap was opened, and the mixture was filtered to obtain the crude product. The crude product, YNU-5a–YNU-5d, was then purified by Al2O3 column chromatography using CH2Cl2 / MeOH (v / v, 1:100–1:40) as the eluent. The yields were 85.4–92.6%.
[0057] Example 3 :
[0058] In a 15.0 cm thick-walled drug-resistant tube, 1.0 mmol of coumarin derivatives pyc1–pyc4 and an equimolar amount of cis-Ru(DMSO)4Cl2 were added, followed by 3.0 mL of a methanol and dichloromethane mixture (v / v, 1:10). After capping the drug-resistant tube, the mixture was reacted at 84 °C for 3 days. The mixture was then cooled to room temperature, the cap was opened, and the mixture was filtered to obtain the crude product. The crude product, YNU-5a–YNU-5d, was then purified by Al2O3 column chromatography using CH2Cl2 / MeOH (v / v, 1:100–1:40) as the eluent. The yields were 85.4–92.6%.
[0059] To fully illustrate the pharmaceutical applications of the four novel coumarin ruthenium anticancer compounds YNU-5a–YNU-5d described in this invention, the applicant conducted in vitro and in vivo antitumor activity experiments on them.
[0060] I. Experimental Study on the Inhibitory Activity of Four Novel Coumarin Ruthenium Anticancer Compounds YNU-5a–YNU-5d on Two Human Cell Lines
[0061] 1. Cell lines and cell culture
[0062] This experiment used two human cell lines: A549 / DDP, a drug-resistant human lung cancer cell line, and HEK293, a normal human embryonic kidney cell line.
[0063] All human cell lines were cultured in RPMI-1640 medium containing 100 U / mL penicillin, 10 wt% fetal blood, and 100 U / mL streptomycin, and incubated at 37°C in an incubator containing 5% CO2 by volume.
[0064] 2. Preparation of the test compound
[0065] All compounds used must have a purity of ≥95%. Their DMSO stock solutions were diluted with physiological buffer to a final solution of 20 mmol / L (final DMSO concentration ≤1%). The inhibitory effect of each compound on the growth of normal cells or selected tumor cells at this concentration was then tested.
[0066] 3. Cell growth inhibition assay (CCK-8 assay)
[0067] (a) Cells were digested, counted, and prepared to a concentration of 5 × 10⁻⁶. 4 Add 100 μL of cell suspension per well to each well of a 96-well cell culture plate;
[0068] (b) Incubate the 96-well cell culture plate in a 37°C, 5% CO2 incubator for 24 h;
[0069] (c) Dilute the drug to the required concentration with RPMI-1640 medium and add 100 μL of the corresponding drug-containing medium to each well of a 96-well plate to achieve final concentrations of 0, 1.0, 2.5, 5.0, 10.0 and 20.0 μM, respectively. Set up 6 parallel experiments for each concentration.
[0070] (d) Place the 96-well cell culture plate in a 37°C, 5% CO2 incubator for 48 h;
[0071] (e) Perform CCK-8 staining at λ=450 nm and measure the OD value;
[0072] Add 10 μL of CCK-8 to each well and incubate for 2 h. Gently mix by shaking for 10 min. Measure the OD value of each well at a wavelength of λ=450 nm using a microplate reader and calculate the inhibition rate. Use the formula:
[0073]
[0074] The inhibition rate of each compound on the growth of the selected cells was calculated, and then the IC50 of each tested compound on each selected cell line was calculated using the Bliss method. 50 The values are shown in Table 2 below.
[0075]
[0076] Table 2 shows that YNU-5a–YNU-5d has a good inhibitory effect on the human lung cancer drug-resistant cell line A549 / DDP, with an IC50 concentration of 100%. 50 The values were 15.36 ± 0.72, 11.29 ± 0.63, 7.05 ± 0.96, and 5.02 ± 0.14 µM, respectively, which were much greater than those of pyc1–pyc4 (>20 µM), cis-Ru(DMSO)4Cl2 (>20 µM), and the clinical drug cisplatin (>20 µM). The study also found that YNU-5a–YNU-5d had low toxicity to normal HEK293 cells (>20 µM), indicating that the complex YNU-5a–YNU-5d has a selective inhibitory effect on the proliferation of human lung cancer drug-resistant cell line A549 / DDP.
[0077] In summary, the four novel coumarin ruthenium anticancer compounds YNU-5a–YNU-5d exhibited superior antitumor activity and overcame cisplatin resistance, demonstrating potential medicinal value and promising applications in the preparation of various antitumor drugs.
[0078] The foregoing description of specific exemplary embodiments of the invention is for illustrative and explanatory purposes. These descriptions are not intended to limit the invention to the precise forms disclosed, and it will be apparent that many changes and variations can be made in accordance with the foregoing teachings. The exemplary embodiments were chosen and described in order to explain the specific principles of the invention and its practical application, thereby enabling those skilled in the art to implement and utilize various different exemplary embodiments of the invention, as well as various different choices and variations. The scope of the invention is intended to be defined by the claims and their equivalents.
Claims
1. A novel coumarin-ruthenium anticancer complex, characterized in that, The novel coumarin ruthenium anticancer compound is complex 1 or complex 2; The structural formula of the complex 1 is as follows:
2. The structural formula of the complex 2 is as follows:
3. Among them, R1 is H or CH3; R2 is H or OCH3; R3 is H.
4. The novel coumarin-ruthenium anticancer complex according to claim 1, characterized in that, The synthesis method of complex 1 or complex 2 is as follows: 1.0 mmol of coumarin derivative pyc1–pyc4 and an equal amount of cis-Ru(DMSO)4Cl2 are added to a 15.0 cm thick-walled drug-resistant tube, followed by 3.0 mL of a mixed solution of methanol and dichloromethane (v / v, 1:10). After capping the drug-resistant bottle, the mixture is reacted at 50-90℃ (68℃ being the optimal temperature) for 3 days. After cooling to room temperature, the cap is opened, and the mixture is filtered to obtain the crude product. Then, using CH2Cl2 / MeOH (v / v, 1:100~1:40) as the eluent, the product is purified by Al2O3 column chromatography to obtain a reddish-brown product, which is complex 1 or complex 2.
5. The novel coumarin-ruthenium anticancer complex according to claim 1, characterized in that, The structural formula of the coumarin derivative is as follows: or 6. Among them, R1 is H or CH3; R2 is H or OCH3; R3 is H.
7. The application of the novel coumarin ruthenium anticancer complex according to claim 1 in the preparation of antitumor drugs.
8. The application according to claim 5, characterized in that, The tumor is human lung cancer.
9. An in vitro and in vivo antitumor drug, characterized in that, The in vitro and in vivo antitumor drug uses the novel coumarin ruthenium anticancer complex as described in claim 1 as its active ingredient.
